Trials / Conditions / Refractory Angioimmunoblastic T-Cell Lymphoma

Refractory Angioimmunoblastic T-Cell Lymphoma

7 registered clinical trials studyying Refractory Angioimmunoblastic T-Cell Lymphoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma NCT04795869	Northwestern University	Phase 2
Active Not Recruiting	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas NCT03598998	City of Hope Medical Center	Phase 1 / Phase 2
Active Not Recruiting	Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or NCT03593018	The Lymphoma Academic Research Organisation	Phase 3
Active Not Recruiting	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin NCT03278782	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma NCT03075553	Mayo Clinic	Phase 2
Recruiting	A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820	Mayo Clinic	Phase 1
Completed	Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Periph NCT01590732	M.D. Anderson Cancer Center	Phase 1